MX2020004837A - Inhibidores de la vía de adenosina para el tratamiento del cáncer. - Google Patents
Inhibidores de la vía de adenosina para el tratamiento del cáncer.Info
- Publication number
- MX2020004837A MX2020004837A MX2020004837A MX2020004837A MX2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A MX 2020004837 A MX2020004837 A MX 2020004837A
- Authority
- MX
- Mexico
- Prior art keywords
- pathway inhibitors
- cancer treatment
- adenosine pathway
- adenosine
- elevated levels
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/05—Immunological preparations stimulating the reticulo-endothelial system, e.g. against cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ecology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Se proporcionan en la presente, entre otros, los métodos para tratar el cáncer en sujetos que expresan niveles elevados de receptores A2A de adenosina, y opcionalmente que expresan niveles elevados de CD73 y/o PD-L1, mediante la administración de inhibidores de la vía de adenosina.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762582246P | 2017-11-06 | 2017-11-06 | |
PCT/US2018/059480 WO2019090347A1 (en) | 2017-11-06 | 2018-11-06 | Adenosine pathway inhibitors for cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020004837A true MX2020004837A (es) | 2020-08-13 |
Family
ID=66332406
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020004837A MX2020004837A (es) | 2017-11-06 | 2018-11-06 | Inhibidores de la vía de adenosina para el tratamiento del cáncer. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210008206A1 (es) |
EP (1) | EP3706753A4 (es) |
JP (1) | JP2021502342A (es) |
KR (1) | KR20200096921A (es) |
CN (1) | CN111565722A (es) |
AU (1) | AU2018359894A1 (es) |
CA (1) | CA3080976A1 (es) |
IL (1) | IL274445A (es) |
MX (1) | MX2020004837A (es) |
WO (1) | WO2019090347A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180103918A (ko) * | 2015-12-24 | 2018-09-19 | 코버스 파마슈티칼스, 인크. | 암을 치료하는 방법 |
BR112020000962A2 (pt) | 2017-07-18 | 2020-07-14 | Nuvation Bio Inc. | compostos de 1,8-naftiridinona e usos dos mesmos |
CA3070273A1 (en) | 2017-07-18 | 2019-01-24 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
EP3820522A4 (en) | 2018-07-12 | 2022-05-18 | Corvus Pharmaceuticals, Inc. | METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY |
JP2022517419A (ja) | 2019-01-18 | 2022-03-08 | ニューベイション・バイオ・インコーポレイテッド | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
CN113939291A (zh) | 2019-01-18 | 2022-01-14 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
US20220241313A1 (en) * | 2019-03-12 | 2022-08-04 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
JP2023522730A (ja) * | 2020-04-22 | 2023-05-31 | アケソ・バイオファーマ・インコーポレイテッド | 抗cd73/抗pd-1二重特異性抗体及びその使用 |
WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
US20170242016A1 (en) * | 2014-10-15 | 2017-08-24 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for therapy targeting pd-l1 |
KR20180103918A (ko) * | 2015-12-24 | 2018-09-19 | 코버스 파마슈티칼스, 인크. | 암을 치료하는 방법 |
US20190284293A1 (en) * | 2016-03-04 | 2019-09-19 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
-
2018
- 2018-11-06 CA CA3080976A patent/CA3080976A1/en not_active Abandoned
- 2018-11-06 EP EP18873427.1A patent/EP3706753A4/en not_active Withdrawn
- 2018-11-06 JP JP2020524525A patent/JP2021502342A/ja active Pending
- 2018-11-06 US US16/761,749 patent/US20210008206A1/en not_active Abandoned
- 2018-11-06 CN CN201880085439.5A patent/CN111565722A/zh active Pending
- 2018-11-06 WO PCT/US2018/059480 patent/WO2019090347A1/en unknown
- 2018-11-06 KR KR1020207016103A patent/KR20200096921A/ko unknown
- 2018-11-06 AU AU2018359894A patent/AU2018359894A1/en not_active Abandoned
- 2018-11-06 MX MX2020004837A patent/MX2020004837A/es unknown
-
2020
- 2020-05-04 IL IL274445A patent/IL274445A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20200096921A (ko) | 2020-08-14 |
CN111565722A (zh) | 2020-08-21 |
EP3706753A4 (en) | 2021-12-22 |
WO2019090347A1 (en) | 2019-05-09 |
CA3080976A1 (en) | 2019-05-09 |
WO2019090347A8 (en) | 2019-06-13 |
EP3706753A1 (en) | 2020-09-16 |
US20210008206A1 (en) | 2021-01-14 |
JP2021502342A (ja) | 2021-01-28 |
AU2018359894A1 (en) | 2020-05-21 |
IL274445A (en) | 2020-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020004837A (es) | Inhibidores de la vía de adenosina para el tratamiento del cáncer. | |
CL2019000820A1 (es) | Compuestos, composiciones y sus usos para inhibir la actividad arginasa. (divisional solicitud 201801134) | |
DOP2019000266A (es) | Inhibidores de pd-1/pd-l1 | |
CO2019007839A2 (es) | Composiciones y métodos para inhibir la acción de la arginasa | |
NI201900019A (es) | Inhibidores de procesos metabólicos celulares | |
CY1121831T1 (el) | Παραγωγα θειενο [2,3-c] πυρρολ-4-ονης ως αναστολεις της erk | |
CL2018003316A1 (es) | Compuestos para la inhibición de k-ras y para el tratamiento del cáncer. (divisional solicitud 201702786) | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
BR112016017700A2 (pt) | método para tratamento de um câncer em um indivíduo, medicamento, kit, método, uso ou kit, e, método, medicamento ou kit | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
EA201691866A1 (ru) | Проникающие в опухоль лимфоциты для адоптивной клеточной терапии | |
CO2017004525A2 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
PE20180260A1 (es) | Metodos y kits para tratar la depresion | |
AR102553A1 (es) | Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit | |
CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
CR20150316A (es) | Compuestos y sus métodos de empleo | |
BR112018008503A2 (pt) | método para tratar câncer de pulmão de células pequenas, método para tratar um sujeito, método para selecionar um sujeito com câncer | |
CL2017000317A1 (es) | Terapia adjuntiva con 25-hidroxi vitamina d | |
CO2020001107A2 (es) | Moduladores terapéuticos del modo inverso de la atp sintasa | |
MX2016009655A (es) | Metodos novedosos para el tratamiento del cancer. | |
BR112015024703A2 (pt) | formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose | |
ECSP13012988A (es) | Derivados de tienopirimidina (2,3-d) y su uso para tratar arritmia | |
CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
BR112017006190A2 (pt) | agentes terapêuticos humanos |